AL102

Phase 3Small molecule

IImmunome, Inc.

AL102 is one of 2 small molecule programs targeting Desmoid Tumor. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Desmoid TumorActive, not recruiting

Desmoid TumorPhase 3

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Desmoid Tumor

#DrugCompanyPhaseTrials

Vivia

SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Approved

4 2

AL102

IImmunome, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Active, not recruiting

Desmoid Tumor

NCT04871282

Clinical

Trials by Indication[1]

Desmoid Tumor1 trial

A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting·IImmunome, Inc.·Phase 2/3·NCT04871282·198 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AL102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AL102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AL102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Immunome, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IImmunome, Inc.

AL102

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Desmoid Tumor1 trial

References

Drug Info

Quick Facts

Related News